Abstract
Introduction

34
Francisella tularensis is a Gram-negative bacterium that is the causative agent of resistant to some antibiotics such as beta-lactams [3, 6] and polymyxins [7, 8] . In addition, drug 44 resistance to conventional antibiotic treatments may be emerging in this species [9, 10] , and there 45 is a concern about potentially engineered resistance in the biothreat context. Because of this,
46
there is interest in developing new potential treatments for tularemia [3] .
47
Francisella lipopolysaccharide (LPS). We down-selected the set of peptides based on 71 cytotoxicity, and tested the efficacy of our lead peptides in two infection models: first in the 72 waxworm (Galleria mellonella) and then in a murine tularemia pneumonic infection model. were then diluted to the appropriate concentration needed. All work with F. tularensis SchuS4
86
was performed in a BSL-3 laboratory following strict safety guidelines.
87
Peptide synthesis. Peptides were synthesized by ChinaPeptides, Inc (Shanghai, China) using
88
Fmoc chemistry. Peptide was provided at >95% purity, which was confirmed with RP-HPLC
89
and ESI-MS. Sequences and physico-chemical properties are shown in Table 1 .
90
Peptide properties. Physico-chemical properties including charge, hydrophobic moment and 91 hydrophobicity as well as helical wheels were calculated using Heliquest [21] . In addition, the 92 APD defined total hydrophobic ratio was calculated with the APD3 website [22] .
93
Minimal inhibitory concentration (MIC) determination assay. 
203
For organ burden studies, mice were infected and treated as above and sacrificed on Day 
Results:
211
Peptide design and properties:
212 Apo6 is a naturally occurring (native) peptide identified intact from American alligator 213 blood by de novo peptide mass-spectrometry sequencing [16, 17] . It is the C-terminal sequence 214 of alligator apolipoprotein E, and was discovered using our BioProspector process [16] .
215
A series of Apo6 derivative peptides, designated GATR-1 through GATR-7 (Table 1) ,
216
were generated by introducing changes in the original Apo6 sequence, in order to improve the 217 peptide's amphipathicity, hydrophobic face, or net charge, as described below. 
227
GATR-3 combines the T2/V13 and E8/E15/D19 amino acid substitutions of GATR-1 and 228 GATR-2. These sequence modifications increase the overall peptide charge to +7, hydrophobic 229 moment to 0.523 µH, and net hydrophobicity to 0.226.
230
GATR-4 was produced by adding NP to the N-terminus because N-capping peptides,
231
particularly with a proline residue, has been reported to increase peptide stability and decrease 232 protease susceptibility [34] . Add numbers about charge, HM and H from table. 
238
In GATR-6, the sequence of GATR-5 has been further modified by replacing the lysine 239 (K) residues K11, K12, K14, K16, and K18 with arginine (R) residues. The physicochemical 240
properties of GATR-6 are nearly identical to those of GATR-5 and also GATR-3. Both GATR-5 241 and GATR-6 have a net charge of +7, hydrophobic moments of 0.566 µH and 0.568 µH 242 respectively, and hydrophobicities of 0.289 H and 0.284 H respectively.
243
GATR-7 was produced from the GATR-6 sequence by substituting the lysine (K) at 244 position 1 with arginine (R), the phenylalanine (F) at position 2 to tryptophan (W), the 245 phenylalanine (F) at position 6 to tryptophan (W) and the histidine (H) at position 9 to arginine 246 (R). Due to these substitutions, GATR-7 is predicted to have a net charge of +8, which is higher 247 than that of the other GATR peptides. Additionally, the hydrophobic moment of GATR-7 is 248 0.578 µH and its net hydrophobicity is calculated to be 0.273 H. These values are similar to 249 those calculated for GATR-3, GATR-5 and GATR-6.
250
GATR peptides are antibacterial against Francisella tularensis. concentrations tested. In addition, GATR-1, GATR-2, GATR-3, and GATR-4 were found to be 259 inactive under these conditions; however, some inhibitory activity was observed when GATR-5,
260
GATR-6, and GATR-7 are tested, with 85% inhibition at 41.5 µg/ml in the case of GATR-7
261
( Figure 1 ). It appears that the antibacterial activity in media increases along with the 262 hydrophobic moment. at a lower concentration of 1 µg/ml. However, GATR-3, GATR-6, and GATR-7 do not show 311 significant pore formation compared to the untreated bacteria at 1 µg/ml. LL-37 was used as 312 positive control in the depolarization and pore formation studies of the peptides [19, 28] . hydrophobicity (GATR-6 and GATR-7) bind this LPS in greater amounts than do less charged 337 and hydrophobic peptides (GATR-3 and GATR-5). Thus, LPS binding might contribute to the 338 anti-Francisella mechanism of the GATR peptides.
313
GATR peptides bind F. tularensis LVS lipopolysaccharide (LPS).
339
Toxicity of the GATR peptides
340
We sought to further down-select the peptides by testing for potential toxicity. To 341 examine whether the GATR peptides may be toxic to mammalian cells (particularly those 342 peptides with higher charge), we performed hemolysis assays, cytotoxicity assays using the MTT 343 assay, and toxicity experiments in G. mellonella waxworms. First, hemolysis assays using sheep 344 red blood cells were performed at peptide concentrations of 100 µg/ml for 1 h [19, 31, 34] .
345
GATR-5, -6, and -7 showed statistically significant hemolysis, in particular GATR-6 and GATR-346 7, each of which had hemolysis levels of greater than 20% of RBCs ( Figure 4A) period, waxworms treated with GATR-3, GATR-6, and GATR-7 were not found to have 356 significant death as measured by larvae survival (Figure 4D) Apo6 and GATR peptides, with GATR-3 having the strongest effect (80% survival, p=0.0001).
375
The parent peptide, Apo6, was the next best candidate (60% survival, p=0.0002). While GATR- succumbed to infection by 120 h (0% survival, p=0.0008). GATR-6-(30% survival, p=0.045)
378
and GATR-7-(30% survival p value= 0.0015) treated waxworms also showed significant 379 prolonged survival.
380
Murine model in vivo 381
After down-selecting our lead peptides through the G. mellonella invertebrate model, the 382 3 lead peptides were tested in a murine model of pulmonary tularemia. GATR-3, GATR-6, and
383 GATR-7 were tested. In addition, we tested Apo6, Figure 6A 394 and 7B.
395
In the first set of experiments, mice (5/group) were given 1 prophylactic peptide 396 treatment 1 day before infection (Day -1) and 3 treatments after infection at 3, 24, and 48 h. Each 397 intra-peritoneal (IP) injection delivered 5 mg/kg of peptide. Survival is shown in Figure 6A . In 398 this model, GATR-3 was found to be the most successful peptide, with 60% survival (p=0.0047)
399
compared to the PBS-injected control, which had a mean time till death (MTD) of 6 days and 0%
400
survival. GATR-6 saved 40% of mice (p=0.0237) compared to the control. GATR-7 saved 20% 401 of mice, but Mantel-Cox tests indicate this was not significant (p=0.0736). When average health 402 scores were examined in Figure 6B , GATR-3 delayed the time of disease onset from day 1 to 403 day 3 and lessened severity of clinical signs over the course of infection. GATR-6 and GATR-7
404
did not delay disease onset, but severity of signs were slightly lessened compared to the 405 untreated control. For this set of experiments, mice were weighed daily in the morning. Weights 406 from day 4 are compared in Figure 6C . None of the GATR peptide treated mice show a 407 significant difference in weight change compared to the untreated control.
408
In the second set of experiments, the prophylactic pre-treatment was not given and larger 409 groups were used (10 mice/group). Mice received only the 3 treatments after infection at 3, 24, 410 and 48 h. Because LL-37, D-LL-37, and GATR-7 were not found to significantly rescue mice in 411 the first set of studies, they were not used in these experiments. Only GATR-3 and GATR-6 412 were tested. In the survival study shown in Figure 6D , GATR-3 once again was the most 413 successful peptide, with 50% survival (p=0.0053) compared to the untreated control, which had 414 10% survival and a mean time till death of 5.5 days. However, GATR-6 was not found to have 415 significant survival in this study (10% survival, p=0.4347), though mean time till death (MTD)
416 was extended to 6 days. This may indicate the prophylactic treatment was important for the 417 efficacy of GATR-6. When average health scores were compared in Figure 6E , differences 418 between peptide-treated and untreated groups were not as apparent as in Figure 6B . All groups 419 had signs of disease onset on day 3. Disease signs of GATR-3-treated mice were only slightly 420 lessened compared to the untreated group, while signs of GATR-6-treated mice were slightly 421 more severe than the untreated mice.
422
Because GATR-3 rescued mice in both sets of experiments, an organ burden study was 423 performed with this peptide on day 4 to determine the bacterial burden in the lungs, spleen, and 424 liver (3 mice/group), as shown in Figure 6F . Though no significant difference was found 425 between the bacterial burden in the spleens and livers of GATR-3-treated and untreated mice, the 426 bacterial numbers were found to be significantly lower in lungs (p<0.0001). Thus, the survival 427 benefit may have been due to reduced lung burden as opposed to overall bacterial clearance. with the synthetic peptides with F. tularensis, we examined membrane binding and disruption.
471
DiSC 3 (5) measures depolarization and transient holes in a previously hyperpolarized membrane.
472
It was found that as hydrophobicity and cationicity increase, so does depolarization activity.
473
However, this is not the case when the ethidium bromide uptake assay was performed, which 474 measures larger pores or disruption that allow the passage of ethidium bromide into the cell.
475
While Apo6 shows significant membrane disruption at both 10 and 1 µg/ml tested, none of the 476 other peptides show significant depolarization at 1 µg/ml. 
492
After dropping one peptide (GATR-5) for toxicity issues, the 3 best performing peptides,
493
GATR-3, GATR-6, and GATR-7, were tested for activity in vivo. has the advantage of protease resistance, which should allow it to circulate in the body longer.
512
When D-LL-37 was tested in this model, this peptide was also ineffective at rescuing infected 513 mice or even prolonging mean time till death. Thus, LL-37 is not effective against a pulmonary-514 based tularemia infection when given systemically, in agreement with previous reports [20] .
515
When the GATR peptides were tested in this model with a prophylactic treatment, it was 516 found that both GATR-3 and GATR-6 peptide treatments significantly rescued mice infected 517 with F. tularensis LVS. GATR-7 did not, though this peptide had the strongest activity in MIC 518 assays, which are considered the gold standard for activity [19, 24] . In a second set of 519 experiments, GATR-3 and GATR-6 were tested in larger groups without the prophylactic 520 treatment. GATR-3 maintained its efficacy without the prophylactic treatment, while 
